We need to talk about the good and the bad fibroblasts - the dangerous fibroblasts that overgrow organs and destroy organ function, but also the necessary specialized fibroblasts in bone, the osteoblasts.
Pathological bone remodeling phenotypes
The success in biomedical sciences such as genomics and proteomics is not paralleled in the medical product development methods. The consequence of this is a lack of translation into improved drug safety and efficacy. Therefore, some antifibrotic treatments have deleterious effects on bone fibroblasts and may have side effects.
Proposed phenotypes of endochondral bone formation in rheumatic diseases
Findings have identified bone as a possible endocrine organ and the availability of valid biochemical bone markers suggests that assessing bone turnover should also play an important role in general safety pharmacology.
With our bone inflammation panel, you can assess whether your treatment is having a deleterious effect.
Related publications:
Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?
Biochemical markers in osteoarthritis with lessons learned from osteoporosis
Role of biochemical markers in the management of osteoporosis
Please don't hesitate to contact us if you have any questions or other inquiries.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
